English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) represent the standard of care as first-line treatment for patients with non-small-cell lung cancer (NSCLC) harbouring EGFR mutation. There are few treatment options after progression from TKI. In the absence of targetable mutations, patients who develop resistance are usually treated with chemotherapy. There are limited data focusing the role of TKI re-treatment. We present the case of a patient who achieved clinical benefit and objective response upon re-treatment with a first-generation anti-EGFR TKI.

Effective tyrosine kinase inhibitor re-treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer patient: a case report